In vitro activities of antimicrobial cationic peptides; melittin and nisin, alone or in combination with antibiotics against Gram-positive bacteria

Journal of Chemotherapy

Volumn 24, Issue 3, 2012, Pages 137-143

  Dosler, Sibel ^a   Alev Gerceker, A ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Combination; In vitro activity; Melittin; Nisin; Time killing curve

Indexed keywords

AMPICILLIN; DAPTOMYCIN; ERYTHROMYCIN; LINEZOLID; MELITTIN; NISIN; VANCOMYCIN;

ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BROTH DILUTION; CONTROLLED STUDY; DRUG POTENTIATION; ENTEROCOCCUS FAECALIS; GRAM POSITIVE INFECTION; IN VITRO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN;

ANTI-BACTERIAL AGENTS; CELLS, CULTURED; DRUG THERAPY, COMBINATION; ENTEROCOCCUS FAECALIS; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MELITTEN; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; NISIN; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 84866263004     PISSN: 1120009X     EISSN: 19739478     Source Type: Journal    
DOI: 10.1179/1973947812Y.0000000007     Document Type: Article

References (27)

1. Rosenthal VD, Maki DG, Mehta A, Alvarez-Moreno C, Leblebicioglu H, Higuera F, et al. International Nosocomial Infection Control Consortium report, data summary for 2002-2007, issued January 2008. Am J Infect Control. 2008;36(9):627-637.
2. Fluckiger U, Widmer AF. Epidemiology of methicillin-resistant Staphylococcus aureus. Chemotherapy. 1999;45:121-134.
3. Maltezou HC, Giamarellou H. Community-acquired methicillin-resistant Staphylococcus aureus infections. Int J Antimicrob Agents. 2006;27:87-96.
4. Cookson BD, Macrae MB, Barrett SP, Brown DF, Chadwick C, French GL, et al. Combined Working Party of the Hospital Infection Society and Infection Control Nurses Association. Guidelines for the control of glycopeptide-resistant enterococci in hospitals. J Hosp Infect. 2006;62:6-21.
5. French GL. The continuing crisis in antibiotic resistance. Int J Antimicrob Agents. 2010;36(3):3-7.
6. Donadio S, Maffioli S, Monciardini P, Sosio M, Jabes D. Antibiotic discovery in the twenty-first century: current trends and future perspectives. J Antibiot. 2010;63(8):423-30.
7. Hancock RE, Chapple DS. Peptide antibiotics. Antimicrob Agents Chemother. 1999;43(6):1317-1323.
8. Raghuraman H, Chattopadyay A. Melittin: a membrane-active peptide with diverse functions. Biosci Rep. 2007;27:189-223.
9. Zendo T, Yoneyama F, Sonomoto K. Lactococcal membrane-permeabilizing antimicrobial peptides. Appl Microbiol Biotechnol. 2010;88:1-9.
10. Bierbaum G, Sahl HG. Lantibiotics: mode of action, biosynthesis and bioengineering. Curr Pharm Biotechnol. 2009,10(1): 2-18.
11. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Informational Supplement. 16th ed. M100-S20. Wayne (PA): CLSI; 2010.
12. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved Guideline. 7th ed. M7-A7. Wayne (PA): CLSI; 2006.
13. Giacometti A, Cirioni O, Barchiesi F, Del Prete MS, Fortuna M, Caselli F, et al. In vitro susceptibility tests for cationic peptides: comparison of broth microdilution methods for bac- teria that grow aerobically. Antimicrob Agents Chemother. 2000;44(6):1694-1696.
14. Steinberg DA, Hurst MA, Fujii CA, Kung AH, Ho JF, Cheng FC, et al. Protegrin-1: a broad-spectrum, rapidly microbicidal peptide with in vivo activity. Antimicrob Agents Chemother. 1997;41(8):1738-1742.
15. National Committee for Clinical Laboratory Standards. Methods for Determining Bactericidal Activity of Antimicrobial Agents. Approved Guideline. M26-A. Wayne (PA): NCCLS; 1999.
16. Pillai SK, Moellering Jr RC, Eliopoulos GM. Antimicrobial Combinations. In: Lorian V, editor. Antibiotics in laboratory medicine. 5th ed. Philadelphia (PA): Lippincott Williams and Wilkins; 2005.
17. Odds FC. Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother. 2003;52:1.
18. Wiesnar J, Vilcinskas A. Antimicrobial peptides: the ancient arm of the human immune system. Virulence. 2010;1(5):440-464.
19. Hancock RE, Sahl HG. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat Biotechnol. 2006;24:1551-1557.
20. Brumfitt W, Salton MR, Hamilton-Miller JM. Nisin, alone and combined with peptidoglycan-modulating antibiotics: activity against methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci. J Antimicrob Chemother. 2002; 50(5):731-734.
21. Piper C, Draper LA, Cotter PD, Ross RP, Hill C. A comparison of the activities of lacticin 3147 and nisin against drug-resistant Staphylococcus aureus and Enterococcus species. J Antimicrob Chemother. 2009;64(3):546-551.
22. Food and Drug Administration. Nisin preparation: affirmation of GRAS status as a direct human food ingredient. Fed Regist. 1988;53:11247-51.
23. Cleveland J, Montville TJ, Nes IF, Chikindas MOL. Bacteriocins: safe, natural antimicrobials for food preservation. Int J Food Microbiol. 2001;71:1-20.
24. Kramer NE, Smid EJ, Kok J, de Kruijff B, Kuipers OP, Breukink E. Resistance of gram-positive bacteria to nisin is not determined by lipid II levels. FEMS Microbiol Lett. 2004;239:157-61.
25. Cao Y, Yu RQ, Liu Y, Zhou HX, Song LL, Cao Y, et al. Design, recombinant expression, and antibacterial activity of the cecropins-melittin hybrid antimicrobial peptides. Curr Microbiol. 2010;61(3):169-75.
26. Yeaman MR, Yount NY. Mechanisms of antimicrobial peptide action and resistance. Pharmacol Rev. 2003;55:27-55.
27. 2 on methicillin-resistant nosocomial isolates of Staphylococcus aureus and interactions with clinically used antibiotics. Diagn Microbiol Infect Dis. 2004;49(3):197-200.